BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update

- Q3 2023 ORLADEYO net revenue of $85.7 million (+29.8 percent y-o-y) --

- Company expects to achieve no less than $320 million in full year 2023 ORLADEYO revenue and $1 billion in peak ORLADEYO revenue -

- Net cash utilization of $16.5 million in Q3 2023 (-43.9 percent y-o-y) -

- Company to host R&D Day on Friday, November 3rd to introduce additional therapies from its pipeline -

RESEARCH TRIANGLE PARK, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

“With nearly three years of launch data, we have excellent visibility into the pattern of growth for ORLADEYO and we remain on track to achieve the no less than $320 million in ORLADEYO revenues we have expected for 2023. Our solid base and the consistent addition of new patients each quarter, combined with the ongoing improvement in our percentage of paid patients and launches in new global markets, are all driving peak revenues to $1 billion,” said Jon Stonehouse, president and chief executive officer of BioCryst.

Program Updates

ORLADEYO® (berotralstat): Oral, Once-daily Treatment for Prevention of Hereditary Angioedema (HAE) Attacks

“Strong, steady new patient switches continue to fuel the growth in ORLADEYO as more and more patients want to experience the benefits of the only oral, once-daily therapy to prevent HAE attacks,” said Charlie Gayer, chief commercial officer of BioCryst.

• ORLADEYO net revenue in the third quarter of 2023 was $85.7 million (+29.8 percent year-over-year (y-o-y)).
• Total growth in patients taking ORLADEYO continued on a strong, linear trajectory.
• The ongoing APeX-P trial in pediatric HAE patients who are 2 to